May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Evaluation of Anti–Adenoviral Effect of Anti–HIV Agents in vitro
Author Affiliations & Notes
  • A. Fuchigami
    Ophthalmology, Fukuoka, Fukuoka, Japan
  • E. Uchio
    Ophthalmology, Fukuoka, Fukuoka, Japan
  • A. Hayashi
    Mitsubishi Chemical BCL, Tokyo, Japan
  • H. Ishiko
    Mitsubishi Chemical BCL, Tokyo, Japan
  • K. Aoki
    Ophthalmology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
  • S. Ohno
    Ophthalmology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan
  • Footnotes
    Commercial Relationships  A. Fuchigami, None; E. Uchio, None; A. Hayashi, None; H. Ishiko, None; K. Aoki, None; S. Ohno, None.
  • Footnotes
    Support  Grant–in–aid for Scientific Research by JSPS15591869
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 3056. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Fuchigami, E. Uchio, A. Hayashi, H. Ishiko, K. Aoki, S. Ohno; Evaluation of Anti–Adenoviral Effect of Anti–HIV Agents in vitro . Invest. Ophthalmol. Vis. Sci. 2006;47(13):3056.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Around one million people are suffered from adenoviral keratoconjunctivitis in a year and it is recognized as one of the major pathogens of ophthalmological nosocomial infection in Japan. Although cidofovir may be used systemically for immunocompromised patients in disseminated adenoviral infection, no specific anti–adenoviral agent is established for the treatment of adenoviral infection. We have evaluated anti–adenoviral effect of anti–HIV agents in this study.

Methods: : Five anti–HIV agents, zalcitabin, sanilbudine, nevirapine, indinavir and amprenavir were enrolled in the in vitro evaluation. A549 cells were used for viral cell culture and adenovirus serotypes 3, 4, 8, 19 and 37 were used. After calculating CC50 of each agent by MTS method, adenovirus was cultivated with the agents for seven days and extracted adenoviral DNA was quantitatively measured by real–time PCR.

Results: : Among anti–HIV drugs, zalcitabin and sanilbudine, nucleoside reverse transcriptase inhibitors, showed significant anti–adenoviral activity, and in contrast, nevirapine, non–nucleoside reverse transcriptase inhibitor, and indinavir and amprenavir, protease inhibitors, were ineffective to adenovirus.

Conclusions: : These results indicate that zalcitabin and sanilbudine are possible candidates of adenoviral infection including keratoconjunctivitis and anti–adenoviral effect might depend on the pharmacological property among anti–HIV agents. Chemical property, clinical safety for systemic and local application should be surveyed for these drugs to be accepted for the treatment of adenovirus in clinical situation.

Keywords: antiviral drugs • adenovirus • conjunctivitis 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.